Elevated levels of kynurenate have been observed in the postmortem brain tissue of individuals with schizophrenia, while rats treated with kynurenine-3-monooxygenase inhibitors have reduced prepulse inhibition, indicating the dopaminergic hyperactivity associated with schizophrenia [40,41]. This evidence concerns the gene KMO and schizophrenia.